L R Roberto Moscoso, MD
Cardiovascular Disease · Corona, CANPI 1073548962
Payments from drug & device makers
Across 289 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$729
- AstraZeneca$686
- Merck$534
- Boehringer Ingelheim$499
- Pfizer$334
- Johnson & Johnson$323
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,55398%
- Education$872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 53 | $729 |
| AstraZeneca | 40 | $686 |
| Merck | 25 | $534 |
| Boehringer Ingelheim | 21 | $499 |
| Pfizer | 14 | $334 |
| Johnson & Johnson | 20 | $323 |
| E.r. Squibb & Sons, L.L.C. | 16 | $309 |
| Sanofi-aventis U.S. LLC | 10 | $208 |
| Amgen | 8 | $201 |
| Bayer | 9 | $176 |
| Scpharmaceuticals Inc. | 6 | $159 |
| Philips North America LLC | 7 | $147 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $143 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $118 |
| Astellas Pharma US Inc | 4 | $118 |
| Medtronic | 4 | $110 |
| Abiomed | 4 | $108 |
| Edwards Lifesciences | 4 | $105 |
| Esperion Therapeutics, Inc. | 6 | $104 |
| Irhythm Technologies, Inc. | 3 | $90 |
| Novo Nordisk | 3 | $69 |
| Chiesi USA, Inc. | 2 | $50 |
| Cleerly, Inc. | 1 | $48 |
| Bardy Diagnostics, Inc. | 3 | $42 |
| Boston Scientific | 2 | $40 |
| Biotronik Inc. | 1 | $29 |
| Atricure, Inc. | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $23 |
| Cvrx, Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| GSK | 1 | $14 |
| Gilead | 1 | $14 |
How this compares
$5,640 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 396 | $414,521 |
| EntrestoSacubitril/Valsartan | 174 | $174,845 |
| XareltoRivaroxaban | 65 | $82,028 |
| JardianceEmpagliflozin | 72 | $68,433 |
| FarxigaDapagliflozin Propanediol | 30 | $35,130 |
| MultaqDronedarone Hcl | 30 | $32,536 |
| Repatha SureclickEvolocumab | 30 | $16,664 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $10,062 |
| Ezetimibe | 172 | $3,806 |
| Atorvastatin Calcium | 428 | $3,667 |
| Midodrine Hcl | 36 | $2,728 |
| Metoprolol Succinate | 158 | $2,050 |
| Amiodarone Hcl | 55 | $1,614 |
| Rosuvastatin Calcium | 85 | $1,512 |
| Potassium Chloride | 74 | $1,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $334 | $414,521396 claims |
| NovartisEntresto | $729 | $174,845174 claims |
| Johnson & JohnsonXarelto | $323 | $82,02865 claims |
| Boehringer IngelheimJardiance | $499 | $68,43372 claims |
| AstraZenecaFarxiga | $686 | $35,13030 claims |
| Sanofi-aventis U.S. LLCMultaq | $208 | $32,53630 claims |
| Esperion Therapeutics, Inc.Nexlizet | $104 | $10,06214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Corona
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.